Hangzhou Xianwei Da: Enoglutide can reduce weight by over 15%, and may be approved as early as the beginning of 2026.

Hangzhou Xian Da Life Science and Technology Co., Ltd. announced that its drug Enoctenatide resulted in a weight loss of over 15% after 48 weeks at the highest dose. CEO Pan Hai stated that while the trial did not directly compare Enoctenatide with existing drugs, the results were very similar to the previous Chinese study on Lilly's Zepbound. Enoctenatide is a once-weekly injectable drug currently undergoing regulatory review in China for the treatment of obesity and diabetes, with potential approval as early as the beginning of 2026. Xian Da Life Science is in early discussions with potential partners to develop the drug overseas. Pan Hai emphasized that based on the results presented at the American Diabetes Association annual meeting and published in The Lancet, approximately 92.8% of participants experienced a weight loss of more than 5%, which is higher than the 85%-87% observed in the Chinese trials of Wegovy and Zepbound. Once approved, Xian Da Life Science's Enoctenatide will compete with Novo Nordisk's Wegovy and Lilly's Zepbound in the market, with Sinda BioPharma as a competitor in the Chinese market. The drug initially licensed from Lilly by Sinda BioPharma has shown similar weight loss effects to Zepbound and is expected to be approved soon.